Adrestia Therapeutics secures Series A funding from global pharmacy company GSK

Adrestia Therapeutics secures Series A funding from global pharmacy company GSK. Founder Steve Jackson says “"The Adrestia team have done a fantastic job. We are now looking forward with great excitement to achieving great things in 2021 and beyond".

The multi-year collaboration agreement seeks to discover novel drug targets across a number of therapeutic areas by combining Adrestia’s Disease Rebalancing Platform and GSK’s leading position in human genetics and functional genomics.

Adrestia’s Disease Rebalancing Platform uses synthetic viability to identify phenotypic and molecular imbalances of disease as the basis of novel drug discovery.